Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Filters applied. Clear filters
. 2023 Nov 22;23(1):461.
doi: 10.1186/s12890-023-02762-4.

Tea consumption and risk of lung diseases: a two‑sample Mendelian randomization study

Affiliations

Tea consumption and risk of lung diseases: a two‑sample Mendelian randomization study

Linjie Chen et al. BMC Pulm Med. .

Abstract

Background: Numerous studies have reported the association between tea intake and lung diseases. However, the probable relationship between tea consumption on lung diseases still remain controversial and it is unclear whether these findings are due to reverse causality or confounding factor.

Methods: In order to systematically investigate the causal connection between tea intake on respiratory system disorders, we employed a two-sample Mendelian randomized (MR) study. Genetic instruments for tea intake were identified from a genome-wide association study (GWAS) involving 447,385 individuals. Data on lung diseases were collected from a variety of publicly available genome-wide association studies. The main method used for MR analysis is the inverse variance weighting (IVW) method. To ensure the accuracy of the findings, further sensitivity analysis was conducted.

Results: The IVW method in our MR analysis revealed no evidence to support a causal relationship between tea intake and lung diseases (IPF: OR = 0.997, 95% CI = 0.994-1.000, p = 0.065; Lung cancer: OR = 1.003, 95% CI = 0.998-1.008, P = 0.261; COPD: OR = 1.001, 95% CI = 0.993-1.006, p = 0.552; acute bronchitis: OR = 0.919, 95% CI = 0.536-1.576, p = 0.759; tuberculosis: OR = 1.002, 95% CI = 0.998-1.008, p = 0.301; pneumonia: OR = 0.789, 95% CI = 0.583-1.068, p = 0.125). The reliability of the results was further demonstrated by four additional MR analysis techniques and additional sensitivity testing.

Conclusion: We found no evidence of a link between tea intake on lung diseases in our MR results based on genetic information.

Keywords: COPD; IPF; Lung cancer; Lung diseases; Mendelian randomization; Tea consumption.

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing interests.

Figures

Fig. 1
Fig. 1
Design of Mendelian randomization study of tea intake and lung diseases The instrumental variable in this Mendelian randomization study was based on the hypothesis that it was related to tea intake but not to confounding variables, and that it only impacted the risk of six lung diseases through tea intake
Fig. 2
Fig. 2
Forest plot showed the causal association between tea intake and lung disease. (A) IPF; (B) lung cancer; (C) COPD; (D) acute bronchitis; (E) tuberculosis; (F) pneumonia. OR, odds ratio; 95% CI, 95% confidence interval; IPF, idiopathic pulmonary fibrosis; COPD, chronic obstructive pulmonary diseases
Fig. 3
Fig. 3
MR leave-one-out sensitivity analysis of tea intake on lung disease. Circles indicate the results of MR analysis of remaining SNPs on tea intake on lung disease after omitting each SNP in turn. Bars indicate CI. (A) IPF; (B) lung cancer; (C) COPD; (D) acute bronchitis; (E) tuberculosis; (F) pneumonia
Fig. 4
Fig. 4
Estimating heterogeneity using funnel plots of individual causal relationships between tea intake and lung disease. (A) IPF; (B) lung cancer; (C) COPD; (D) acute bronchitis; (E) tuberculosis; (F) pneumonia

Similar articles

References

    1. Mokra D, Adamcakova J, Mokry J. Green Tea Polyphenol (-)-Epigallocatechin-3-Gallate (EGCG): a time for a New Player in the treatment of Respiratory Diseases? Antioxid (Basel) 2022;11:1566. doi: 10.3390/antiox11081566. - DOI - PMC - PubMed
    1. GBD 2019 Chronic Respiratory Diseases Collaborators Global burden of chronic Respiratory Diseases and risk factors, 1990–2019: an update from the global burden of Disease Study 2019. EClinicalMedicine. 2023;59:101936. doi: 10.1016/j.eclinm.2023.101936. - DOI - PMC - PubMed
    1. Krishnan JK, Rajan M, Banerjee S, et al. Race and sex differences in mortality in individuals with Chronic Obstructive Pulmonary Disease. Ann Am Thorac Soc. 2022;19:1661–8. doi: 10.1513/AnnalsATS.202112-1346OC. - DOI - PMC - PubMed
    1. Gibson GJ, Loddenkemper R, Lundbäck B, Sibille Y. Respiratory health and Disease in Europe: the new European lung White Book. Eur Respir J. 2013;42:559–63. doi: 10.1183/09031936.00105513. - DOI - PubMed
    1. MacNee W. Oxidative stress and lung inflammation in airways Disease. Eur J Pharmacol. 2001;429:195–207. doi: 10.1016/s0014-2999(01)01320-6. - DOI - PubMed